Stay updated on Oncolytics Biotech Press Releases

Sign up to get notified when there's something new on the Oncolytics Biotech Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Oncolytics Biotech Press Releases page

  1. Check
    2 days ago
    Change Detected
    Summary
    The investor overview lists recent clinical supply agreements and research findings, along with an upcoming annual meeting, in place of older press releases. The displayed stock price and daily change have also been updated.
    Difference
    3%
    Check dated 2026-11-15T04:08:30.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The displayed stock price rose from $0.42 to $0.44, with the daily change updating from -$0.003 (-0.70%) to -$0.01 (-2.23%). The latest press release now highlights translational data showing pelareorep drives HPV-specific immune responses in anal cancer patients, replacing an update on the GOBLET study and PanCAN grant payment.
    Difference
    3%
    Check dated 2026-11-08T05:22:03.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The investor overview now shows a share price of $0.42, down $0.003 (0.70%), and features an October 27, 2026 press release on pelareorep’s durability and survival data in anal cancer. It replaces the prior quote and an October 12, 2026 release about patent protection and the intellectual property portfolio.
    Difference
    3%
    Check dated 2026-11-01T03:11:12.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The latest press release now highlights a planned ESMO presentation on pelareorep’s potential in colorectal cancer, replacing a release about immune responses in liver cancer. The stock quote’s daily change shifted from a decline of $0.05 (−9.12%) to a gain of $0.002 (0.40%).
    Difference
    2%
    Check dated 2026-10-25T03:17:28.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The stock quote changed from $0.56, up $0.013 (2.39%), to $0.50, down $0.05 (9.12%). The latest press releases now cover a GOBLET study update and patent protection extending into the late 2040s, replacing earlier colorectal cancer study and preclinical-results announcements.
    Difference
    3%
    Check dated 2026-10-18T02:59:53.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    Oncolytics Biotech’s displayed share price changed from $0.63 to $0.56. The daily movement shifted from a $0.01 decline (−1.56%) to a $0.013 gain (+2.39%).
    Difference
    0.9%
    Check dated 2026-10-11T06:50:48.000Z thumbnail image

Stay in the know with updates to Oncolytics Biotech Press Releases

Enter your email address, and we'll notify you when there's something new on the Oncolytics Biotech Press Releases page.